Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Insmed ( (INSM) ) has provided an update.
On February 18, 2025, Alfred Altomari announced he would not seek re-election to Insmed’s board at the company’s 2025 Annual Meeting, though this decision was not due to any disagreements with the company. Insmed reported significant financial performance in 2024, with ARIKAYCE generating $363.7 million in revenue, marking a 19% annual growth. The company is also progressing with its drug Brensocatib, which received FDA Priority Review, and anticipates a U.S. launch in 2025 if approved. Insmed’s ongoing research and development efforts, including its robust pipeline and pre-clinical programs, position it for continued growth and expansion in the biopharmaceutical industry.
More about Insmed
Insmed Incorporated is a global biopharmaceutical company focusing on delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The company is known for its products like ARIKAYCE, and it has a strong market presence in regions including the U.S., Japan, and Europe.
YTD Price Performance: 19.84%
Average Trading Volume: 1,799,204
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $14.56B
For detailed information about INSM stock, go to TipRanks’ Stock Analysis page.
